Quarterly ResultMay 27, 2026, 08:02 AM
Mesa Laboratories FY26 Revenue +3.4% to $249.1M; Operating Income +13.3%
AI Summary
Mesa Laboratories reported a 3.4% increase in full fiscal year 2026 revenues to $249.1 million and a 13.3% rise in operating income to $18.5 million. For the fourth quarter of fiscal year 2026, revenues grew 2.6% to $63.7 million and operating income surged 87% to $2.7 million. The company repaid $14.7 million of debt in 4Q26, reducing its Total Net Leverage Ratio to 2.11. Challenges in the Biopharmaceutical Development division due to commercial execution and export controls were noted, while the Sterilization and Disinfection Control division showed strong growth.
Key Highlights
- Full FY26 revenues increased 3.4% to $249.1 million.
- Full FY26 operating income increased 13.3% to $18.5 million.
- 4Q26 revenues increased 2.6% to $63.7 million.
- 4Q26 operating income increased 87% to $2.7 million.
- Repaid $14.7 million of debt in 4Q26, reducing Net Leverage Ratio to 2.11.
- SDC division 4Q26 organic revenue grew 17.7% to $29.1 million.
- BPD division 4Q26 organic revenue declined 29.9% to $8.8 million.
- Clinical Genomics 4Q26 organic revenue grew 5.8% to $12.2 million.
Price Impact
More from MLAB